Dyadic announces first quarter 2024 financial results and highlights recent company progress
Human health sector final clinical study report has been issued for the first-in-human phase 1 clinical trial demonstrating safety and antibody response for dyai-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against covid-19 infection entered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companies successfully expressed a h1n1 influenza antigen in our collaboration with the vaccine and immunotherapy center (“vic”) at massachusetts general hospital announced strategic partnership to develop affordable rabies prophylactics and vaccines using c1-cell protein production platform published a manuscript of preclinical studies on c1 produced monoclonal antibody in non-human primates and hamsters in prestigious peer-reviewed journal nature communications advanced collaboration with israel institute for biological research (iibr) targeting bio-threats and emerging disease solutions c1 produced adjuvanted recombinant ferritin nanoparticle h5n1 “bird flu” human vaccine candidate demonstrated a strong immune response in animal studies animal health sector c1 produced adjuvanted recombinant ferritin nanoparticle h5n1 “bird flu” human vaccine candidate demonstrated a strong immune response in animal studies for potential use in poultry, cattle and other animals expanded collaboration with phibro/abic to develop vaccines and treatments for companion and livestock animal diseases alternative proteins sector executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin advanced development of 6 product candidates for non-pharmaceutical applications utilizing the dapibus™ platform technology corporate closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrants appointed mr. patrick lucy as board chairman and mr.
DYAI Ratings Summary
DYAI Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission